Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs CleanSpark Inc (CLSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs CleanSpark Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while CleanSpark Inc trades at $13.65 (market cap $3.45B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 2.3× CleanSpark Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, CleanSpark Inc nearer its low. Which is the better fit depends on your goals.
| BIO | CLSK | |
|---|---|---|
Market Cap | $8.04B | $3.45B |
Sector | Health | Technology |
52-Week High | $339.75 | $23.20 |
52-Week Low | $241.71 | $8.18 |
Enterprise Value | $7.85B | $4.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
CleanSpark (CLSK) trades at $12.36, down 3.81% today, with a bearish technical signal and recent earnings misses. The company reported a net loss margin of -67.66% for 2026 but announced a transformative $6.6 billion 20-year AI data center lease, shifting focus from Bitcoin mining to high-performance computing. Analyst consensus remains unanimously bullish with a $21.43 price target, highlighting growth potential despite current profitability challenges.
The outlook balances high growth potential from the AI pivot against significant execution risks and persistent losses. Near-term volatility is expected as the market assesses the company's ability to monetize new contracts and achieve sustainable profitability. The stock presents a high-risk, high-reward opportunity dependent on successful business model transition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About CleanSpark Inc
CleanSpark is a leading Bitcoin mining company that operates high-density data centers. It focuses on using sustainable energy to power its mining fleet and provides digital infrastructure for the blockchain ecosystem.
Read more on CLSK →
